Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. The company’s product development programs utilize its proprietary long-term drug delivery platform, ProNeura, and focus primarily on treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Product Pipeline Probuphine The company is in the process of developing Probuphine for the maintenance treatment of opioid dependence. Upon subdermal insertion in a patient, Probuphine is designed to release medication continuously and maintain a stable, around the clock blood level of the drug buprenorphine, an approved agent for the treatment of opioid dependence. The company has licensed the rights to commercialize Probuphine in the U.S. and Canada to Braeburn Pharmaceuticals Sprl (Braeburn) and during 2014 the company has been supporting Braeburn and a team of experts to implement the program developed in cooperation with the FDA to address the items in the Complete Response letter issued in April 2013. This includes conducting a double blind, double dummy clinical study of a four implant dose of Probuphine in clinically stable patients who are receiving maintenance treatment with an approved sublingual formulation containing buprenorphine at a daily dose of 8mg or less. Intellectual Property In 2010, the United States Patent and Trademark Office issued a patent covering methods of using Probuphine for the treatment of opiate addiction. The company is the owner of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and ethylene-vinyl acetate, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent would expire in June 2024. Four U.S. continuation applications are pending which incorporate the use of buprenorphine with the continuous delivery technology. These patent applications include claims related to Probuphine for the potential treatment of opioid addiction and chronic pain. Related patents covering use of Probuphine with the continuous delivery technology for the treatment of opiate addiction have also issued in Australia, Canada, India, Japan, Mexico and New Zealand. Patents covering certain dopamine agonist implants have been issued or allowed in the United States, Europe, Japan, Australia, Canada, South Korea, Mexico, New Zealand, South Africa, and Hong Kong, while prosecution of the patent application continues in the United States, Israel, India, Japan, and China. The company holds a license from Sanofi-Aventis under certain issued U.S. patents and certain issued foreign patents relating to iloperidone and its methods of use in the treatment of psychiatric disorders, psychotic disorders and analgesia. The term of the U.S. patent that covers certain aspects of its iloperidone product expires in October 2016, excluding a six month extension possible if an approval of pediatric indication is obtained. History Titan Pharmaceuticals, Inc. was founded in 1992.
titan pharmaceuticals inc (TTNP:OTC US)
400 Oyster Point Boulevard
South San Francisco, CA 94080
|Alkermes PLC||$60.70 USD||+1.14|
|Reckitt Benckiser Group PLC||5,655 GBp||-102.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact TITAN PHARMACEUTICALS INC, please visit www.titanpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.